$DRIO
DarioHealth Corp.

2022 Q4 Form 10-Q Financial Statement

#000155837022017769 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $6.809M $6.605M
YoY Change 12.96% 17.34%
Cost Of Revenue $4.077M $4.805M
YoY Change -25.6% 55.15%
Gross Profit $2.732M $1.800M
YoY Change 398.54% 117.92%
Gross Profit Margin 40.12% 27.25%
Selling, General & Admin $6.960M $11.57M
YoY Change -58.81% -35.07%
% of Gross Profit 254.76% 642.78%
Research & Development $4.782M $4.803M
YoY Change -10.05% -12.77%
% of Gross Profit 175.04% 266.83%
Depreciation & Amortization $1.250M $1.226M
YoY Change 73.85% -9.79%
% of Gross Profit 45.75% 68.11%
Operating Expenses $11.74M $16.37M
YoY Change -47.14% -29.8%
Operating Profit -$9.010M -$14.57M
YoY Change -58.41% -35.23%
Interest Expense -$244.0K $93.00K
YoY Change -280.74% 57.63%
% of Operating Profit
Other Income/Expense, Net -$24.00K -$1.059M
YoY Change 0.0% -2025.45%
Pretax Income -$12.61M -$15.63M
YoY Change -41.48% -30.35%
Income Tax $3.000K $0.00
% Of Pretax Income
Net Earnings -$12.88M -$15.63M
YoY Change -40.32% -30.35%
Net Earnings / Revenue -189.19% -236.67%
Basic Earnings Per Share $0.64
Diluted Earnings Per Share -$0.50 $0.64
COMMON SHARES
Basic Shares Outstanding 23.30M 22.98M
Diluted Shares Outstanding 22.97M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.52M $57.26M
YoY Change 37.56% 11.0%
Cash & Equivalents $49.36M $57.08M
Short-Term Investments $165.0K $176.0K
Other Short-Term Assets $239.0K
YoY Change 214.47%
Inventory $7.956M $7.762M
Prepaid Expenses
Receivables $6.416M $4.521M
Other Receivables $1.630M $2.042M
Total Short-Term Assets $65.52M $71.58M
YoY Change 43.68% 20.86%
LONG-TERM ASSETS
Property, Plant & Equipment $788.0K $858.0K
YoY Change 12.25% 20.34%
Goodwill $41.64M $41.64M
YoY Change 0.0% 5.69%
Intangibles $9.916M $11.05M
YoY Change -20.42% -36.51%
Long-Term Investments
YoY Change
Other Assets $117.0K $27.00K
YoY Change 51.95% -64.94%
Total Long-Term Assets $53.67M $54.75M
YoY Change -2.72% -5.53%
TOTAL ASSETS
Total Short-Term Assets $65.52M $71.58M
Total Long-Term Assets $53.67M $54.75M
Total Assets $119.2M $126.3M
YoY Change 18.28% 7.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.914M $1.982M
YoY Change 74.48% -50.33%
Accrued Expenses $2.185M $270.0K
YoY Change -50.32% -7.85%
Deferred Revenue $1.320M $990.0K
YoY Change 10.46% -18.38%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $8.823M
YoY Change
Total Short-Term Liabilities $19.35M $11.52M
YoY Change 27.29% -9.12%
LONG-TERM LIABILITIES
Long-Term Debt $18.11M $24.05M
YoY Change
Other Long-Term Liabilities $1.737M $1.818M
YoY Change 105.32% 2654.55%
Total Long-Term Liabilities $19.84M $25.86M
YoY Change 94385.71% 39087.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.35M $11.52M
Total Long-Term Liabilities $19.84M $25.86M
Total Liabilities $39.19M $37.39M
YoY Change 157.47% 193.31%
SHAREHOLDERS EQUITY
Retained Earnings -$285.9M -$273.0M
YoY Change 28.75% 36.52%
Common Stock $3.000K $2.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $80.00M $88.95M
YoY Change
Total Liabilities & Shareholders Equity $119.2M $126.3M
YoY Change 18.28% 7.81%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$12.88M -$15.63M
YoY Change -40.32% -30.35%
Depreciation, Depletion And Amortization $1.250M $1.226M
YoY Change 73.85% -9.79%
Cash From Operating Activities -$7.941M -$10.70M
YoY Change -47.54% -13.99%
INVESTING ACTIVITIES
Capital Expenditures $59.00K -$174.0K
YoY Change -186.76% 81.25%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$59.00K -$174.0K
YoY Change -86.71% 79.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 265.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -7.941M -10.70M
Cash From Investing Activities -59.00K -174.0K
Cash From Financing Activities 265.0K 0.000
Net Change In Cash -7.735M -10.87M
YoY Change -50.35% -13.27%
FREE CASH FLOW
Cash From Operating Activities -$7.941M -$10.70M
Capital Expenditures $59.00K -$174.0K
Free Cash Flow -$8.000M -$10.52M
YoY Change -46.91% -14.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.64
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.18
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.98
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22973197
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16473449
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22876397
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16202541
dei Entity Central Index Key
EntityCentralIndexKey
0001533998
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16573420
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23291008
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11927
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
9912
us-gaap Revenue Practical Expedient Remaining Performance Obligation
RevenuePracticalExpedientRemainingPerformanceObligation
true
CY2022Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37704
dei Entity Registrant Name
EntityRegistrantName
DarioHealth Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2973162
dei Entity Address Address Line1
EntityAddressAddressLine1
18 W. 18th St.
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10011
dei Trading Symbol
TradingSymbol
DRIO
dei City Area Code
CityAreaCode
972
dei Local Phone Number
LocalPhoneNumber
770-6377
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23296754
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57081000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35808000
CY2022Q3 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
176000
CY2021Q4 us-gaap Restricted Investments Current
RestrictedInvestmentsCurrent
192000
CY2022Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
4521000
CY2021Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1310000
CY2022Q3 us-gaap Inventory Net
InventoryNet
7762000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2042000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2067000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
71582000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45605000
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
6000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
20000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1174000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
287000
CY2022Q3 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
21000
CY2021Q4 drio Long Term Assets Noncurrent
LongTermAssetsNoncurrent
57000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
858000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
702000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
11053000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12460000
CY2022Q3 us-gaap Goodwill
Goodwill
41640000
CY2021Q4 us-gaap Goodwill
Goodwill
41640000
CY2022Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
54752000
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
55166000
CY2022Q3 us-gaap Assets
Assets
126334000
CY2021Q4 us-gaap Assets
Assets
100771000
CY2022Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1982000
CY2021Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5109000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
990000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1195000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
270000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
266000
CY2022Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6512000
CY2021Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
7806000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1770000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
825000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24046000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11524000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15201000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
817000
CY2022Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1001000
CY2022Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
25864000
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
21000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23291008
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16573420
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
9912
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11927
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
361912000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
307561000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-272968000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222014000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
88946000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126334000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100771000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6605000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5629000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20847000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14485000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4805000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4803000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13924000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
11070000
CY2022Q3 us-gaap Gross Profit
GrossProfit
1800000
CY2021Q3 us-gaap Gross Profit
GrossProfit
826000
us-gaap Gross Profit
GrossProfit
6923000
us-gaap Gross Profit
GrossProfit
3415000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4803000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5506000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11903000
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
7571000
CY2021Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
10696000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
26403000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18865000
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
27476000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3999000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7123000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13453000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
16373000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
23325000
us-gaap Operating Expenses
OperatingExpenses
54723000
us-gaap Operating Expenses
OperatingExpenses
58244000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14573000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22499000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47800000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54829000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1059000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
55000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1775000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-346000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15632000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22444000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-49575000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55175000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15632000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22444000
us-gaap Net Income Loss
NetIncomeLoss
-49576000
us-gaap Net Income Loss
NetIncomeLoss
-55175000
CY2022Q3 drio Deemed Dividend
DeemedDividend
-494000
CY2021Q3 drio Deemed Dividend
DeemedDividend
-488000
drio Deemed Dividend
DeemedDividend
-1378000
drio Deemed Dividend
DeemedDividend
-1520000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16126000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22932000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50954000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56695000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.64
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.98
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22973197
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16473449
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22876397
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16202541
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
99652000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
29000
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
43000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
609000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4245000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-15632000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
88946000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3381000
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
887000
drio Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-137000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3224000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
85549000
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
190000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
230000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2467000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
11011000
drio Issuance Of Common Stock And Prefunded Warrants Net Of Issuance Cost
IssuanceOfCommonStockAndPrefundedWarrantsNetOfIssuanceCost
38023000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
134000
us-gaap Net Income Loss
NetIncomeLoss
-49576000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
88946000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
118113000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
34000
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1705000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
303000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2121000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4607000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22444000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
104439000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28151000
us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
133000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256000
drio Warrants Issued During Period Exercise Of Warrants Value
WarrantsIssuedDuringPeriodExerciseOfWarrantsValue
633000
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4078000
us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
303000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4918000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9238000
drio Stock Issued During Period Value Common Stock
StockIssuedDuringPeriodValueCommonStock
64877000
us-gaap Net Income Loss
NetIncomeLoss
-55175000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
104439000
us-gaap Profit Loss
ProfitLoss
-49576000
us-gaap Profit Loss
ProfitLoss
-55175000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
13898000
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
18670000
us-gaap Depreciation
Depreciation
243000
us-gaap Depreciation
Depreciation
202000
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6605000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
5629000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20847000
CY2022Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1339000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
714000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6423000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
5514000
CY2022Q3 us-gaap Inventory Net
InventoryNet
7762000
CY2021Q4 us-gaap Inventory Net
InventoryNet
6228000
us-gaap Inventory Write Down
InventoryWriteDown
22000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
73000
CY2022Q3 drio Aggregative Consideration
AggregativeConsideration
2650000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 54pt;"><span style="font-family:'Helvetica';font-size:8pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;">Preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and judgments that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities, which are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. These estimates are based on management's knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.</p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57081000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51331000
CY2022Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
124000
CY2021Q3 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
197000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57205000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51528000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14485000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3211000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1125000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
129000
drio Increase Decrease In Other Accounts Receivable And Prepaid Expenses And Long Term Assets
IncreaseDecreaseInOtherAccountsReceivableAndPrepaidExpensesAndLongTermAssets
221000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1534000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-96000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-3136000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1401000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1368000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-205000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-139000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
800000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-173000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
945000
drio Non Cash Financial Expenses
NonCashFinancialExpenses
807000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39904000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35273000
drio Payments For Proceeds From Acquire Leases Held For Investment
PaymentsForProceedsFromAcquireLeasesHeldForInvestment
2000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
399000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
193000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
115000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-514000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7690000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
38023000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64877000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
633000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
256000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
23786000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
134000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61675000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65766000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
21257000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
22803000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35948000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28725000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57205000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51528000
us-gaap Interest Paid Net
InterestPaidNet
969000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1177000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
80000
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Operating Income Loss
OperatingIncomeLoss
-47800000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39904000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57081000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1195000
CY2022Q3 drio New Performance Obligations
NewPerformanceObligations
5754000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
-5959000
CY2022Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
990000
CY2022Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
50000000
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q2 drio Line Of Credit Amount Available Subject To Revenue Requirements
LineOfCreditAmountAvailableSubjectToRevenueRequirements
25000000
CY2021Q2 drio Business Acquisition Contingent Consideration Shares
BusinessAcquisitionContingentConsiderationShares
237076
CY2022Q3 drio Reduction In Earnout Threshold Of Revenue
ReductionInEarnoutThresholdOfRevenue
5000000
CY2022Q3 drio Reduction In Earnout Threshold Of Revenue
ReductionInEarnoutThresholdOfRevenue
3000000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
945000
CY2022Q2 us-gaap Line Of Credit Facility Current Borrowing Capacity
LineOfCreditFacilityCurrentBorrowingCapacity
25000000
CY2022Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1930000
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
226586
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.62
CY2022Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P7Y
CY2022Q2 drio Additional Warrant Outstanding Term
AdditionalWarrantOutstandingTerm
P7Y
CY2022Q2 drio Percentage Of Delayed Draw Commitment Amount
PercentageOfDelayedDrawCommitmentAmount
0.06
CY2022Q2 drio Number Of Days Volume Weighted Average Price
NumberOfDaysVolumeWeightedAveragePrice
10
drio Initial Commitment Amount Remeasurement Income
InitialCommitmentAmountRemeasurementIncome
200000
CY2022Q3 drio Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
62000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1878168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.13
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M15D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3861000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
813050
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
115271
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
17.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
409410
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.95
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2166537
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y25D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
131000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2021479
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
131000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
978807
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.72
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M18D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
131000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
26245000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M8D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13898000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18670000
drio Bank Charges
BankCharges
59000
drio Bank Charges
BankCharges
60000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-51000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-322000
us-gaap Investment Income Interest
InvestmentIncomeInterest
228000
us-gaap Investment Income Interest
InvestmentIncomeInterest
36000
us-gaap Interest Expense Debt
InterestExpenseDebt
969000
drio Revaluation Of Long Term Loan
RevaluationOfLongTermLoan
-976000
drio Revaluation Of Warrant Liability
RevaluationOfWarrantLiability
929000
drio Debt Issuance Costs
DebtIssuanceCosts
724000
drio Revaluation Of Financial Commitment Asset
RevaluationOfFinancialCommitmentAsset
-153000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1775000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-346000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6804530
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5987711
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-46336000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48357000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22876397
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16202541
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.98

Files In Submission

Name View Source Status
0001558370-22-017769-index-headers.html Edgar Link pending
0001558370-22-017769-index.html Edgar Link pending
0001558370-22-017769.txt Edgar Link pending
0001558370-22-017769-xbrl.zip Edgar Link pending
drio-20220930.xsd Edgar Link pending
drio-20220930x10q.htm Edgar Link pending
drio-20220930xex31d1.htm Edgar Link pending
drio-20220930xex31d2.htm Edgar Link pending
drio-20220930xex32d1.htm Edgar Link pending
drio-20220930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
drio-20220930_cal.xml Edgar Link unprocessable
drio-20220930_lab.xml Edgar Link unprocessable
drio-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
drio-20220930x10q_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
drio-20220930_def.xml Edgar Link unprocessable